| Overview |
| bs-15407R-PE-Cy5.5 |
| APOBEC3G Polyclonal Antibody, PE-Cy5.5 Conjugated |
| WB |
| Human |
| Specifications |
| PE-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human APOBEC3G |
| 201-300/384 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 60489 |
| Q9HC16 |
| Cytoplasm, Nucleus |
| A3G; ARCD; ARP9; ARP-9; CEM15; CEM-15; MDS019; bK150C2.7; dJ494G10.1; DNA dC->dU-editing enzyme APOBEC-3G; APOBEC-related cytidine deaminase; APOBEC-related protein; APOBEC-related protein 9; Deoxycytidine deaminase; APOBEC3G |
| DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. Exhibits potent antiviral activity against vif-deficient HIV-1. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. Exhibits antiviral activity also against simian immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV). May inhibit the mobility of LTR and non-LTR retrotransposons. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz